Genesis Therapeutics and Eli Lilly entered into a strategic collaboration to discover novel therapies utilizing Genesis’ AI platform.

Two strategic biopharmaceutical collaborations were announced, each merging one company’s innovative biologic technology with a second company that can drive potential therapeutics over the finish line to commercialization.

Private drug discovery company Cerevance reported positive clinical trial results for CVN424, an experimental treatment for Parkinson’s disease.

Hot off the heels of the company’s milestone approval for the unique checkpoint inhibitor Opdualag, Bristol Myers Squibb forged an oncology drug discovery and development deal valued at more than $1 billion with Volastra Therapeutics.

Dubbed Cambridge Crossing, Sanofi’s new U.S. facilities set to open during May 2022 will hold the tools to develop innovative drug discovery platforms for chemistry, protein engineering, structural and synthetic biology, among many other key modalities.

In the summer of 2021, over 200 biopharma executives were surveyed about their changing approaches to building biologic drug development pipelines. This executive summary presents the findings from this outreach.

Galvani Bioelectronics, a clinical-stage company formed through a strategic partnership between GlaxoSmithKline and Verily Life Sciences in 2016 with the aim to develop targeted neuromodulation therapies, announced that the first patient with rheumatoid arthritis was treated through stimulation of the splenic nerve using the its novel bioelectronics platform.

Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.

Engitix Therapeutics raised $54 million in Series A financing. Engitix plans to use the money to boost the company’s drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.

Prellis Biologics entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing the Bay Area biotechnology company’s first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO).